Terms: = Breast cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
2673 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
3. Human Blood Serum Counteracts egfr/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract] [Full Text] [Related]
4. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
5. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative breast cancer.
Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
[TBL] [Abstract] [Full Text] [Related]
6. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
7. Single cell lineage tracing reveals clonal dynamics of anti-egfr therapy resistance in triple negative breast cancer.
Pellecchia S; Franchini M; Viscido G; Arnese R; Gambardella G
Genome Med; 2024 Apr; 16(1):55. PubMed ID: 38605363
[TBL] [Abstract] [Full Text] [Related]
8. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the egfr pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract] [Full Text] [Related]
9. Molecular and functional insight into anti-egfr nanobody: Theranostic implications for malignancies.
Tripathy RK; Pande AH
Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Values of CD8+, PARP, and egfr on Overall Survival in Patients with Triple-Negative breast cancer.
Putri RI; Haryono SJ; Brahma B; Prayitno YH; Sutandyo N
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1025-1034. PubMed ID: 38546085
[TBL] [Abstract] [Full Text] [Related]
11. Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies.
Camorani S; Caliendo A; Morrone E; Agnello L; Martini M; Cantile M; Cerrone M; Zannetti A; La Deda M; Fedele M; Ricciardi L; Cerchia L
J Exp Clin Cancer Res; 2024 Mar; 43(1):92. PubMed ID: 38532439
[TBL] [Abstract] [Full Text] [Related]
12. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
13. Clinical, Epidemiologic, and Pathologic Significance of erbb2-Low Expression in breast cancer.
Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
[TBL] [Abstract] [Full Text] [Related]
14. Uncovering the effect and mechanism of Jiawei Xiaoyao Wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis.
Bai Y; Niu L; Song L; Dai G; Zhang W; He B; San W; Li S
Phytomedicine; 2024 Jun; 128():155427. PubMed ID: 38513380
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract] [Full Text] [Related]
16. Combination treatment with egfr Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative breast cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract] [Full Text] [Related]
17. Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway.
He L; She C; Jiang S; Qi Z; Deng Z; Ji L; Cui Y; Wu J
Biol Direct; 2024 Mar; 19(1):21. PubMed ID: 38459605
[TBL] [Abstract] [Full Text] [Related]
18. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
19. Dysregulated Gab1 signalling in triple negative breast cancer.
Bongartz H; Mehwald N; Seiß EA; Schumertl T; Naß N; Dittrich A
Cell Commun Signal; 2024 Mar; 22(1):161. PubMed ID: 38448989
[TBL] [Abstract] [Full Text] [Related]
20. Synthesis of Indole-Linked Thiadiazoles and their Anticancer Action against Triple-Negative breast cancer.
Gavadia R; Rasgania J; Sahu N; Nimesh S; Loveleen L; Mor S; Jakhar K
Chem Biodivers; 2024 Apr; 21(4):e202302000. PubMed ID: 38427723
[TBL] [Abstract] [Full Text] [Related]
[Next]
